We're Currently Down for Maintenance
Who We Are
Leukotriene Antagonists Modify Allergic Responses (LAMAR)
Leukotrienes are synthesized and stored in several cell types and are released with histamine in response to an allergic challenge.
Blocking leukotrienes prevents or decreases symptoms of acute inflammation such as wheezing, sneezing, itching, redness, and swelling.
Two antileukotrienes (Singulair® and Accolate® ) have been approved as non-steroidal medicines for treating asthma, but neither MSD nor AZ has taken full advantage of the potential to treat allergic diseases by topical administration.
Despite their comparative weakness, antihistamines have been developed (formulated) for topical treatment of allergic conjunctivitis, allergic rhinitis (hay fever) eczema, with sales (generics) exceeding $4bn/year.
LAMAR has identified proprietary topical formulations and devices for the active ingredient of Accolate® (zafirlukast) to treat allergic inflammation.
We are now seeking strategic or institutional investment or collaboration to progress this portfolio for non-steroidal treatments, because:
Leukotriene Antagonism Mitigates Allergic Reactions!